NAS:KROS (USA)

Keros Therapeutics Inc $ 67.15 2.86 (4.45%)

Volume:
190,302
Avg Vol (1m):
194,233
Market Cap $:
1.56 Bil
Enterprise Value $:
1.42 Bil
P/E (TTM):
0.00
P/B:
10.36
Warning! GuruFocus has detected 1 Severe warning sign with KROS. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Keros Therapeutics Inc () from 2020 to Jan 25 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Keros Therapeutics stock (KROS) PE ratio as of Jan 25 2021 is 0. More Details

Keros Therapeutics PE Ratio (TTM) Chart

EMBED

Keros Therapeutics PE Ratio (TTM) Historical Data

Total 207
  • 1
  • 2
  • 3
Keros Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-01-250.0 2020-11-190.0
2021-01-220.0 2020-11-180.0
2021-01-210.0 2020-11-170.0
2021-01-200.0 2020-11-160.0
2021-01-190.0 2020-11-130.0
2021-01-150.0 2020-11-120.0
2021-01-140.0 2020-11-110.0
2021-01-130.0 2020-11-100.0
2021-01-120.0 2020-11-090.0
2021-01-110.0 2020-11-060.0
2021-01-080.0 2020-11-050.0
2021-01-070.0 2020-11-040.0
2021-01-060.0 2020-11-030.0
2021-01-050.0 2020-11-020.0
2021-01-040.0 2020-10-300.0
2021-01-010.0 2020-10-290.0
2020-12-310.0 2020-10-280.0
2020-12-300.0 2020-10-270.0
2020-12-290.0 2020-10-260.0
2020-12-280.0 2020-10-230.0
2020-12-240.0 2020-10-220.0
2020-12-230.0 2020-10-210.0
2020-12-220.0 2020-10-200.0
2020-12-210.0 2020-10-190.0
2020-12-180.0 2020-10-160.0
2020-12-170.0 2020-10-150.0
2020-12-160.0 2020-10-140.0
2020-12-150.0 2020-10-130.0
2020-12-140.0 2020-10-120.0
2020-12-110.0 2020-10-090.0
2020-12-100.0 2020-10-080.0
2020-12-090.0 2020-10-070.0
2020-12-080.0 2020-10-060.0
2020-12-070.0 2020-10-050.0
2020-12-040.0 2020-10-020.0
2020-12-030.0 2020-10-010.0
2020-12-020.0 2020-09-300.0
2020-12-010.0 2020-09-290.0
2020-11-300.0 2020-09-280.0
2020-11-270.0 2020-09-250.0
2020-11-260.0 2020-09-240.0
2020-11-250.0 2020-09-230.0
2020-11-240.0 2020-09-220.0
2020-11-230.0 2020-09-210.0
2020-11-200.0 2020-09-180.0

Keros Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2833
Traded in other countries KROS.USA
Address 99 Hayden Avenue, Suite 120, Building E, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.